Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Indivumed is committed to the advancement of precision oncology solutions by harnessing deep multi-omics data from its highly standardized proprietary tissue bank, bioinformatics and artificial intelligence-integrated advanced data analytics.
RNA-based complementary and companion diagnostics could identify more patients able to receive clinical benefit from cancer therapeutics and increase response rates. Employing its expertise in RNA gene signatures, GeneCentric is developing these novel diagnostics through strategic partnerships with biopharma and diagnostics companies.
Using an aptamer-based approach, SomaLogic can identify up to 7,000 proteins at high levels of specificity, providing real-time precision proteomics for use in the lab and the clinic.
Foresight Diagnostics has developed a platform that detects circulating tumor DNA at levels below one part-per-million, allowing accurate identification of minimal residual disease well below current levels of detection. With testing available for B cell lymphomas and solid tumors, Foresight offers partnering opportunities ranging from investigational through prospective clinical studies and companion diagnostic development.
TransCode Therapeutics has developed an iron oxide nanoparticle–based therapeutic RNA delivery system that maximizes targeted tumor uptake while minimizing clearance. With a lead candidate in metastasis and several preclinical programs targeting other cancers, the company is rapidly expanding its portfolio.
Source BioScience is a leading provider of laboratory services to blue chip biopharma, the UK’s National Health Service, and private hospitals. With global operations expanding in the UK, Ireland, and USA, Source is seeking partners for its analytical and diagnostic services.
With its Oncobiota platform, Micronoma is pioneering the analysis of the cancer microbiome for early cancer detection and creating tools for personalized cancer treatment.
Octave has developed a first-in-class, fully integrated comprehensive Precision Care Solution for the personalized treatment of multiple sclerosis and other neurodegenerative diseases.
